Nanoworx
How can we better harness the potential of nanomedicine? Nanoworx, a new Contract Research Organisation (CRO), has been established to automate and accelerate the production of innovative nanomedicines. With support from a PharmaNL grant, Nanoworx is able to build nanomedicine libraries and use advanced screening techniques to select formulations with the most promising properties for clinical application. The project represents an important step in unlocking the potential of nanomedicine and making this technology accessible to both academic and industrial partners.
Nanoworx’s multidisciplinary team combines expertise in nanotechnology, pharmaceutical sciences and bioengineering, supported by collaborations with Eindhoven University of Technology (TU/e), Pivot Park Screening Centre and Trained Therapeutix Discovery. The project focuses on optimising nanoparticles prior to scale-up, using high-throughput screening, advanced data analysis and data management systems that meet the high standards of the biotech sector.
Nanoworx offers a broadly accessible service for biotech companies, research groups and academic consortia, covering the full trajectory from development and screening to optimisation and scale-up of nanomedicines. The ambition is for the initiative to become fully self-sustaining after the end of the PharmaNL grant and, in time, to expand internationally — particularly into Europe and North America — as a fully-fledged Contract Development and Manufacturing Organisation (CDMO).
Objective
To establish a sustainable infrastructure for nanomedicine development, enabling innovative nanotechnology to become faster, more efficient and more widely accessible, with improved outcomes for clinical use.